Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES

(GILD)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Gilead Sciences : Names Andrew Dickinson Chief Financial Officer

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/15/2019 | 08:57am EST

By Colin Kellaher

Gilead Sciences Inc. (GILD) Tuesday said it named Andrew Dickinson chief financial officer, effective Nov. 1.

The Foster City, Calif., biopharmaceutical company said Mr. Dickinson succeeds Robin Washington, who earlier this year announced plans to retire.

Mr. Dickinson, who joined Gilead in 2016, currently serves as executive vice president of corporate development and strategy and will retain responsibility for those functions, the company said.

Gilead in April said Ms. Washington would remain in an advisory capacity through the completion of the company's reporting of its 2019 financial results early next year.

Write to Colin Kellaher at colin.kellaher@wsj.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES
11/11GILEAD SCIENCES : New Data on Filgotinib in Rheumatoid Arthritis Demonstrate Dur..
AQ
11/11GILEAD SCIENCES : Data Showing Potential for Machine Learning to Advance Underst..
AQ
11/11GILEAD SCIENCES : Announces New Data from Viral Hepatitis Research Programs at T..
AQ
11/11GILEAD SCIENCES : Presents Data on Investigational HIV-1 Capsid Inhibitor GS-620..
AQ
11/08GILEAD SCIENCES : Did You Invest in Gilead Sciences?
BU
11/08GILEAD SCIENCES : Presents Data on Investigational HIV-1 Capsid Inhibitor GS-620..
BU
11/08GILEAD SCIENCES : Data Showing Potential for Machine Learning to Advance Underst..
BU
11/08GILEAD SCIENCES : Announces New Data from Viral Hepatitis Research Programs at T..
BU
11/07GILEAD SCIENCES : United States sues Gilead for patent violation on HIV preventi..
AQ
11/07Health Care Up After Teva, Cardinal Health Reports -- Health Care Roundup
DJ
More news
Financials (USD)
Sales 2019 22 300 M
EBIT 2019 11 501 M
Net income 2019 4 320 M
Finance 2019 3 105 M
Yield 2019 3,93%
P/E ratio 2019 17,8x
P/E ratio 2020 11,0x
EV / Sales2019 3,49x
EV / Sales2020 3,44x
Capitalization 80 919 M
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 78,33  $
Last Close Price 63,96  $
Spread / Highest target 48,5%
Spread / Average Target 22,5%
Spread / Lowest Target -6,19%
EPS Revisions
Managers
NameTitle
Daniel O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
Merdad V. Parsey Chief Medical Officer
George Pratt Shultz Director-Emeritus
Gayle Edlund Wilson Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES2.83%82 753
VERTEX PHARMACEUTICALS23.02%50 394
REGENERON PHARMACEUTICALS-6.72%35 474
WUXI APPTEC CO., LTD.73.14%21 914
GENMAB39.72%14 081
BEIGENE, LTD.39.96%11 493